Efficacy of sorafenib combined with transarterial chemoembolization in the treatment of advanced hepatocellular carcinoma: A meta-analysis

Table 1 Characteristics of included studies in the meta-analysis and systematic review

Ref.	Year	Number of cases	Mean age (years)	Design	Dose of sorafenib	Chemoembolization agents
Zheng et al[18]	2022	32 vs 32	56 vs 55	RCT	400 mg twice daily	Epirubicin, cisplatin, doxorubicin, mitomycin
He et al[16]	2019	125 vs 122	49 vs 49	RCT	400 mg twice daily	Mitomycin, doxorubicin
Kondo et al[17]	2019	35 vs 33	72 vs 71	RCT	400 mg twice daily	Oxaliplatin, fluorouracil, epirubicin
Zhao et al[20]	2019	46 vs 58	NA	Retrospective cohort study	400 mg twice daily	Oxaliplatin, epirubicin
Kudo et al[22]	2018	102 vs 103	67 vs 68	RCT	400 mg twice daily	Cisplatin, fluorouracil
Ikuta et al[19]	2018	26 vs 72	72 vs 69	Retrospective cohort study	400 mg twice daily	Cisplatin, fluorouracil, lipiodol
Ikeda et al[14]	2016	65 vs 41	66 vs 64	RCT	400 mg twice daily	Cisplatin
Bai et al[24]	2013	82 vs 164	54 vs 52	Prospective nonrandomized study	400 mg twice daily	Mitomycin, doxorubicin
Muhammad et al[25]	2013	13 vs 30	61 vs 59	Retrospective cohort study	200 mg increased to 400 mg	Doxorubicin
Sansonno et al[23]	2012	31 vs 31	73 vs 72.8	RCT	400 mg twice daily	Mitomycin, doxorubicin
Qu et al[21]	2012	45 vs 45	51 vs 49	Retrospective study	400 mg twice daily	Oxaliplatin, fluorouracil, epirubicin
Kudo et al[15]	2011	229 vs 229	69 vs 70	RCT	200 mg twice daily	Epirubicin, cisplatin, doxorubicin, mitomycin

NA: Not available; RCT: Randomized controlled trial.